Literature DB >> 15900425

Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients.

Panayiotis Mavroidis1, Massoud al-Abany, Asgeir R Helgason, Anna-Karin Agren Cronqvist, Peter Wersäll, Helena Lind, Eva Qvanta, Kyriaki Theodorou, Constantin Kappas, Bengt K Lind, Gunnar Steineck, Anders Brahme.   

Abstract

BACKGROUND: The estimation of the parameters that describe the dose-response relations of anal sphincter regarding the clinical endpoints of fecal leakage and blood or phlegm in stools is important in the optimization of prostate cancer radiotherapy. Also, the validity of the relative seriality model for this clinical case needs to be examined by associating the clinical follow-up results with the predicted complication rates. PATIENTS AND METHODS: In this study, 65 patients who received radiation therapy for clinically localized prostate adenocarcinoma are analyzed. The clinical treatment outcome and the three-dimensional dose distribution delivered to anal sphincter were available for each patient. A questionnaire was used for assessing the clinical bowel and urinary symptoms. A maximum likelihood fitting was performed to calculate the best estimates of the parameters used by the relative seriality model. The clinical utilization of the calculated parameters in predicting anal sphincter complication probabilities was illustrated by applying the best estimate of the parameters to a subset of the patient population.
RESULTS: The estimated values of the parameters for the two clinical endpoints are D (50) = 70.2 Gy, gamma = 1.22, s = 0.35 for fecal leakage and D (50) = 74.0 Gy, gamma = 0.75, s approximately 0 for blood or phlegm in stools. The standard deviations of the parameters were also calculated together with the confidence intervals of the dose-response curves. The analysis proved that the treatment outcome pattern of the patient material can suitably be reproduced by the relative seriality model (probability of finding a worse fit = 60.2%, the area under the receiver operating characteristic curve = 0.72 and 0.69 and chi(2)-test = 0.97 and 0.86, respectively).
CONCLUSION: Fecal leakage is characterized by a medium relative seriality whereas blood or phlegm in stools was found to have strong volume dependence (low relative seriality). Diminishing the biologically effective uniform dose to anal sphincter < 40-45 Gy may significantly reduce the risk of fecal leakage or blood or phlegm in stools for patients irradiated for prostate cancer.

Entities:  

Mesh:

Year:  2005        PMID: 15900425     DOI: 10.1007/s00066-005-1313-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  12 in total

1.  Comparison of the helical tomotherapy against the multileaf collimator-based intensity-modulated radiotherapy and 3D conformal radiation modalities in lung cancer radiotherapy.

Authors:  P Mavroidis; C Shi; G A Plataniotis; M G Delichas; B Costa Ferreira; S Rodriguez; B K Lind; N Papanikolaou
Journal:  Br J Radiol       Date:  2010-09-21       Impact factor: 3.039

2.  Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer.

Authors:  Hans Geinitz; Reinhard Thamm; Christian Scholz; Christine Heinrich; Nina Prause; Simone Kerndl; Monika Keller; Raymonde Busch; Michael Molls; Frank B Zimmermann
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

3.  Consequences of anorectal cancer atlas implementation in the cooperative group setting: radiobiologic analysis of a prospective randomized in silico target delineation study.

Authors:  Panayiotis Mavroidis; Drosoula Giantsoudis; Musaddiq J Awan; Jasper Nijkamp; Coen R N Rasch; Joop C Duppen; Charles R Thomas; Paul Okunieff; William E Jones; Lisa A Kachnic; Niko Papanikolaou; Clifton D Fuller
Journal:  Radiother Oncol       Date:  2014-07-01       Impact factor: 6.280

Review 4.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

5.  Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer: a comparison between dose-volume constraints and NTCP use.

Authors:  Raffaella Cambria; Barbara A Jereczek-Fossa; Federica Cattani; Cristina Garibaldi; Dario Zerini; Cristiana Fodor; Flavia Serafini; Guido Pedroli; Roberto Orecchia
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

6.  Radiobiologically based treatment plan evaluation for prostate seed implants.

Authors:  Courtney Knaup; Panayiotis Mavroidis; Carlos Esquivel; Dimos Baltas; Sotirios Stathakis; Gregory Swanson; Nikos Papanikolaou
Journal:  J Contemp Brachytherapy       Date:  2011-07-06

7.  Radiobiological evaluation of the influence of dwell time modulation restriction in HIPO optimized HDR prostate brachytherapy implants.

Authors:  Panayiotis Mavroidis; Zaira Katsilieri; Vasiliki Kefala; Natasa Milickovic; Nikos Papanikolaou; Andreas Karabis; Nikolaos Zamboglou; Dimos Baltas
Journal:  J Contemp Brachytherapy       Date:  2010-10-13

8.  Evaluation of the effect of prostate volume change on tumor control probability in LDR brachytherapy.

Authors:  Courtney Knaup; Panayiotis Mavroidis; Sotirios Stathakis; Mark Smith; Gregory Swanson; Niko Papanikolaou
Journal:  J Contemp Brachytherapy       Date:  2011-09-30

9.  Comparison of dose response models for predicting normal tissue complications from cancer radiotherapy: application in rat spinal cord.

Authors:  Magdalena Adamus-Górka; Panayiotis Mavroidis; Bengt K Lind; Anders Brahme
Journal:  Cancers (Basel)       Date:  2011-05-18       Impact factor: 6.639

Review 10.  Transitioning from conventional radiotherapy to intensity-modulated radiotherapy for localized prostate cancer: changing focus from rectal bleeding to detailed quality of life analysis.

Authors:  Hideya Yamazaki; Satoaki Nakamura; Takuya Nishimura; Ken Yoshida; Yasuo Yoshioka; Masahiko Koizumi; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2014-09-08       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.